What is DCN Dx?
DCN Dx specializes in the comprehensive development and manufacturing of diagnostic assays, with a particular focus on lateral flow tests for point-of-use applications. The company provides a full spectrum of services, encompassing contract assay development, clinical research, and regulatory support, all meticulously tailored to client requirements. Their integrated, multidisciplinary team collaborates closely with clients, ensuring a transparent and cooperative process from inception to completion. Operating from a state-of-the-art facility in Carlsbad, California, DCN Dx is dedicated to delivering superior quality outcomes and pioneering solutions within the In Vitro Diagnostics (IVD) industry.
How much funding has DCN Dx raised?
DCN Dx has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
What's next for DCN Dx?
With substantial backing and a clear focus on specialized diagnostic solutions, DCN Dx is well-positioned for continued expansion. The company's large-scale, late-stage funding context suggests a strategic phase focused on scaling operations, enhancing its service offerings, and potentially broadening its market reach. Future developments are likely to involve further innovation in assay technology, expansion of its CDMO/CRO capabilities, and strengthening its partnerships within the healthcare and biotechnology sectors. The company's commitment to end-to-end expertise and client collaboration will be pivotal in navigating the competitive landscape and capitalizing on emerging opportunities in diagnostic innovation.
See full DCN Dx company page
